JTO&EJC: Five-year follow-up data published on two-immunotherapy
1. JTO&EJC: 5-year follow-up data for dual immunotherapy
The study included non-small cell lung cancers from stage IV, which were identified by tissue pathology, and patients who met the entry criteria were randomly divided into Navulyu, one-on-one and further combined two cycles of chemotherapy at a rate of 1:1 (joint treatment group, Navoliu-one-in-one dose of 360 mg, every three weeks; Igi-one-in-one dose of 1 mg/kg, every six weeks) or individual chemotherapy (simple chemotherapy group).
The results showed that at the time of the first data analysis, the median OS was 14.1 and 10.7 months respectively (HR = 0.69), while the median PFS was 6.8 and 5.0 months respectively (HR = 0.70). In summary, the data on the PD-L1 inhibitor combination chemotherapy, which is the result of the PFS ‘ weak positive and OS negative results, provide a basis for further integration of the CTLA-4 inhibitor, which, while prolonging the patient ‘ s survival, poses greater safety problems and financial problems that cannot be ignored.
Click to read original
2. Recent results of the GEOMETRY Mono-1 test: efficacy and safety of Quematini ‘ s treatment of non-small cell lung cancer in the MET exterior 14
The study included patients with MET anomalies/EGFR wild/ALK re-negative NSCLCs and assigned them in different queues (1a, 1b, 2, 3, 4, 5a, 5b, 6 and 7) according to the MT state (METx14 or MT amplification) and treatment lines.
The results show that the overall median follow-up time for first-care patients is 46.4 months (41.8-65.4), for ORRs 68 per cent (55.0-79.7), and for DoRs 16.6 months (8.4-22.1). Of the patients who have been treated in the past, 66.9 months (56.7 – 73.9), 44% (34.1 – 54.3) and 9.7 months (5.6 – 13.0). In any case, the tumour-resistant behaviour is shown by Kamatini, regardless of the patient ‘ s line of treatment, and it is more effective in primary treatment than in previous treatments.
Click to read original
PCR 18.3%! DRAGON IV is in the JCO magazine, and Professor Chu’s team released the results of the first round of the study on pathological mitigation during the end-of-the-horizon “target-free” of stomach cancer.
The study included T3 ~4aN+M0 gland cancer in a combination of stomach and stomach oesophagus, with 1:1 randomly divided into SOXRC groups (SOX+Carellion + Apache) or SOX groups. Patients undergo three cycles of pre-operative treatment, followed by a D2 treatment for stomach cancer. After the operation, the SOXRC group received 3 cycles of SOXC anti-+Apatini+SOX treatment, and then maintenance treatments were provided with Caryary-Cyrus anti-Apatini (up to 17 cycles after Cary-Cyrus anti-surgery and up to 1 year for the total post-Apatini treatment), while SOX received 3 cycles of SOX treatments, followed by S-1 (up to 1 year for the total treatment).
The results showed a significant increase in the pCR rate (18.3 per cent vs. 5.0 per cent) for SOXRC group compared to SOX group, with a margin of 13.7 per cent (OR = 4.5, single side P<0.001). And SOXRC has not increased surgical complications (27% vs 33%) over SOX. In short, the Carrellian Single Anti-+Apatini+Physiotherapy is safe for the gland carcinocinology treatment of stomachs/ gastrophagus combined.
Click to read original
4. Expert consensus on BRAF inhibitors for the treatment of malignant physical tumours (2024 edition)
The increasing incidence of malignant neoplasms in the context of global ageing has increased the disease burden of malignant neoplasms globally, with a projected 28 million new cases of malignant neoplasms in 2040. With the progress of tumour molecular biology research and the widespread application of second-generation sequencing techniques, significant clinical progress has been made in tumour precision treatment. Target-to-BRAF treatment was one of the successful cases of tumour precision medical treatment, and a mutation of the BRAF gene could lead to the unrestricted activation of the filamentary filamentosterase signal-routing downstream stimulator enzymes and promote the rapid growth of tumour cells. There is no consensus in the country that BRAF inhibitors are applied to malignant physical tumours, although individual or combined applications of BRAF inhibitors have been approved for adaptation in a variety of cancers, including melanoma, non-small cell lung cancer, thyroid cancer, colon cancer and cerebrogeloma. The article consolidates clinical evidence of BRAF inhibitors in the field of malignant physical tumours and develops an expert consensus on BRAF inhibitors for the treatment of malignant physical tumours to advance and guide the normative application of BRAF inhibitors in the field of malignant physical tumours.
Click to read original
5. Professor Friedberg: New breakthroughs in advanced HL treatment for N+AVD
The study compares the efficacy and safety of Navulillo ‘ s single anti-AVD (accumin, long-chronic alkali and da carbaryl) (N+AVD) and Wibutuces ‘ mono-anti-AVD (BV+AVD) in the newly diagnosed patients with a typical HL (HL) period III or IV.
The results show that the N+AVD programme has shown significant advantages in improving the PFS for patients. This advantage was further consolidated with the extension of the duration of the follow-up visit (median follow-up 2.1 years). The N+AVD group reaches 92% PFS in 2 years, while the BV+AVD group is 83%, with a risk ratio of 0.45. In sum, this means that the N+AVD programme reduces the risk of disease progress or death by 55 per cent.
Click to read original
6.2024 Nobel Prize for Physiology or Medicine
On 7 October local time, the Swedish School of Medicine, Caroline, announced the award of the Nobel Prize for Physiology or Medicine for 2024 to scientists Victor Ambros and Gary Ruvkun.
Click to read original
7. Zhou Hongxiang Professor ‘s team: The West Dalpenamine Joint Child Sample Treatment can bring significant relief to newly diagnosed ETP-ALL/LBL patients
The study included 54 cases of ETP-ALL/LBL patients and treated them with a combination of tacidinistats.
The results show an EFS rate of 67.7 per cent in three years, an OS rate of 71.5 per cent in three years and a RFS rate of 67.5 per cent in three years. In general, the West Dalpentamine (tucidinestat) Joint Child Sample Programme demonstrated good efficacy and tolerance for newly diagnosed ETP-ALL/LBL patients.
